Goat Polyclonal VEGFA antibody - conjugated to Biotin. Suitable for WB, sELISA and reacts with Recombinant fragment - Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human VEGFA aa 1-200.
IgG
Goat
Biotin
Constituents: PBS, 0.1% BSA
Lyophilized
Polyclonal
WB | sELISA | |
---|---|---|
Recombinant fragment - Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info 0.10000-0.20000 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Recombinant fragment - Human | Dilution info - | Notes - |
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Binding to NRP1 receptor initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity).
Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGFA, VEGF
Goat Polyclonal VEGFA antibody - conjugated to Biotin. Suitable for WB, sELISA and reacts with Recombinant fragment - Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human VEGFA aa 1-200.
Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGFA, VEGF
IgG
Goat
Biotin
Constituents: PBS, 0.1% BSA
Lyophilized
Polyclonal
Affinity purification
Reconstitute in sterile PBS with 0.1% BSA to 0.1 - 1.0 mg/ml.
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
This supplementary information is collated from multiple sources and compiled automatically.
VEGF 165A or Vascular Endothelial Growth Factor 165A is an important protein that plays a role in angiogenesis which is the growth of new blood vessels. Also known as VEGF-A or VEGF isoform 165 this protein has a mass of around 23 kDa when it is in its biotinylated form. VEGF 165A is expressed in various cell types including endothelial cells which form the lining of blood vessels as well as in smooth muscle cells and certain tumor cells. The protein is often targeted in research using anti-VEGF antibodies.
This protein acts directly on endothelial cells to stimulate their proliferation and migration. VEGF 165A is part of a larger family of VEGF proteins that share similar structures and functions. It plays a critical role in both physiological processes like wound healing and pathological conditions like cancer where its expression becomes dysregulated. The protein can bind to receptors on the cell surface initiating cell signaling pathways that lead to angiogenesis.
VEGF 165A functions prominently in the VEGF signaling pathway and the MAPK/ERK pathway. Through these pathways it interacts with other proteins such as VEGF receptors particularly VEGFR-2 to propagate signals leading to angiogenesis and increased vascular permeability. These pathways are vital in ensuring that tissues receive an appropriate blood supply under various conditions including growth and repair processes.
VEGF 165A shows an association with cancer and age-related macular degeneration (AMD). Overexpression of VEGF 165A is linked to tumor growth because it helps form the blood vessels that supply the tumor known as tumor angiogenesis. Similarly in AMD abnormal blood vessel growth driven by VEGF 165A leads to damage in the retina. Anti-VEGF therapies often target this protein to treat these conditions by inhibiting its action on blood vessel formation.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
To detect hVEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μg/ml.
Used in conjunction with compatible secondary reagents the detection limit for recombinant hVEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Lane 1: Marker
Lanes 2-12: 250, 125, 62.5, 31.25, 15.625, 7.8, 3.9, 1.95, 0.975, 0.4875 and 0.24 ng recombinant human VEGF165, respectively.
Non-reducing conditions.
All lanes: Western blot - Biotin Anti-VEGF 165A antibody (ab271201)
Predicted band size: 27 kDa
Human VEGF165 was detected by sandwich ELISA (using 100μl/well) using a concentration of 0.25-1.0 μg/ml of ab271201. This antibody in conjunction with an appropriate capture antibody, allows the detection of at least 0.2-0.4 ng/well of recombinant hVEGF protein.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com